Page 2 - E Poster Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article BOTHELL, Wash., April 13, 2021 /PRNewswire/ -- Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics), an emerging biotechnology company focused on developing a novel MabPair ™ platform for antibody-based combination therapies for the treatment of cancer, inflammation and autoimmune disease, announced a clinical update on its first MabPair product PSB205 at the American Association for Cancer Research (AACR) Annual Meeting. Dr Li Zhang of Sun Yat-Sen University Cancer Centre (SYSUCC), Guangzhou, China presented a poster on Phase 1 Clinical Trial result...

MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021 Investor and Analyst Video Webcast Event on Tuesday, April 13, 2021 at 8:00 AM Eastern Time News provided by Share this article Share this article SAN DIEGO, April 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that vorucic...

Abstract Control Number:  3578 Session Type: E-Poster Session Session Title: Biological Therapeutic Agents Permanent Abstract Number: 959 Abstract Control Number:  3677 Session Type: E-Poster Session Session Title: Biological Therapeutic Agents Permanent Abstract Number: 964 About ST101 ST101 is a peptide inhibitor of C/EBPβ, which is a transcription factor overexpressed in many cancers that regulate cellular differentiation and promote tumor survival and proliferation. ST101 significantly decreases the expression of C/EBPβ target genes/proteins involved in cell survival, proliferati...

Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting Share Article Posters further expand on preclinical immuno-oncology mechanism of action and combination therapy with various checkpoint inhibitors and confirm DRP-104 single agent activity in KEAP1 and STK11 mutant lung tumors and head and neck squamous cell carcinoma New York, NY (PRWEB) April 05, 2021 Dracen Pharmaceuticals, Inc., announced today that three posters profiling its clinical stage glutamine antagonist, DRP-104 (sirpiglenastat), ...

Search jobs 10-Mar-2021 LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today announced that a poster featuring lead clinical candidate LAVA-051 will be presented at week 1 of th...